May 15, 2026
Focus IR Interview – Positive OX-1 Toxicology Results, Partner Interest & Human Trials
Turner Pope Research Note on TheraCryf plc
Turner Pope Investments releases a new research note following positive top-line data from the first toxicology species in TheraCryf's lead Orexin-1 (‘Ox-1’) addiction programme.
Read more
Filter by:
